Mesalazine rectal 1g suppositories (MAX 002) - Aptalis Pharma

Drug Profile

Mesalazine rectal 1g suppositories (MAX 002) - Aptalis Pharma

Alternative Names: 5-ASA 1g rectal suppositories - Aptalis Pharma; MAX 002; MAX-002 1g suppositories - Aptalis Pharma; Mesalamine 1g rectal suppositories - Aptalis Pharma; Mesalazine rectal high-concentration - Aptalis Pharma

Latest Information Update: 07 May 2014

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Axcan Pharma
  • Developer Aptalis
  • Class Aminosalicylic acids; Anti-inflammatories; Irritable bowel syndrome therapies; Small molecules
  • Mechanism of Action Lipoxygenase-cyclooxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Ulcerative proctitis

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 07 May 2014 No development reported - Phase-III for Ulcerative proctitis in Canada (Rectal)
  • 07 May 2014 No development reported - Phase-III for Ulcerative proctitis in Poland (Rectal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top